Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 1/20 | 0.47 |
| ▸ | PTGFR | P43088 | 1/20 | 0.47 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 2/20 | 0.46 |
| ▸ | F10 | P00742 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7084641 | 1.00 | PTGER1 (0.47) | PTGER1PTGFRPTGER3F2F10 | |
| SCHEMBL7081449 | 0.86 | F10 (0.47) | PTGER1PTGFRPTGER3F2F10 | |
| SCHEMBL7081448 | 0.86 | F10 (0.47) | PTGER1PTGFRPTGER3F2F10 | |
| SCHEMBL4654958 | 0.82 | MAPT (0.47) | PTGER1PTGFRPOLBGAAMEN1 | |
| SCHEMBL4656173 | 0.82 | MMP12 (0.55) | POLBGAAMEN1KMT2A | |
| SCHEMBL7081822 | 0.81 | CTSS (0.43) | PTGER1PTGFRPTGER3TAAR1POLB | |
| SCHEMBL901672 | 0.79 | TAAR1 (0.53) | TAAR1MRGPRX4NR3C2 | |
| SCHEMBL3089810 | 0.78 | GAA (0.53) | TAAR1POLBGAAMEN1KMT2A | |
| SCHEMBL28741493 | 0.76 | TAAR1 (0.46) | TAAR1GAANR3C2 | |
| SCHEMBL74878 | 0.76 | SLC7A5 (0.55) | TAAR1GAAMEN1KMT2AMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236302-A1 | Synthetic derivatives | SYNTA PHARMACEUTICALS CORP. | 2003-12-25 | — | — | US | disclosed |
| WO-2003072103-A1 | SYNTHETIC DERIVATIVES | KAVA PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236302-A1 | Synthetic derivatives | CBR1, CBR3, REL | PTGER1 696/4885PTGFR 1203/4885PTGER3 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.